Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide studyPer Soelberg Sørensen, Melinda Magyari, Alex Heick et al.|Multiple Sclerosis and Related Disorders|2022Cited by 42
Ocrelizumab treatment in multiple sclerosis: A Danish population‐based cohort studyLuigi Pontieri, Melinda Magyari, Henrik Kahr Mathiesen et al.|European Journal of Neurology|2021Cited by 29
Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosisThor Ameri Chalmer, Melinda Magyari, Victoria Hansen et al.|Journal of Neurology Neurosurgery & Psychiatry|2019Cited by 20
Patterns and predictors of multiple sclerosis phenotype transitionLuigi Pontieri, Melinda Magyari, Finn Sellebjerg et al.|Brain Communications|2024Cited by 8
Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide studyMalte Roar, Tobias Sejbæk, Finn Sellebjerg et al.|Multiple Sclerosis and Related Disorders|2023Cited by 3